Diabetic Epidemia Outbreack
There are more than 150 million diabetics worldwide, with approximately 90% suffering from type 2 diabetes. An estimated 5 to 6% of the European population (16 million people) suffer from type 2 diabetes. Only about half of these are diagnosed, although routine screening to diagnose diabetes is becoming more common.
The total diabetes market in 2020 was worth 12 billion Euro, and is expected to grow to 18 billion Euro billion by 2025 (Source: S G Cowen).
The Research is expected to grow at 20% per annum, due to more oral drugs becoming available and delaying the need for insulin. The insulin market, valued at 5 billion Euroin 2000, is expected to grow by 16% per annum until 2025, driven by new combinations of insulin formulations including inhalation administration methodologies.
What is Type 2 diabetes?
This is a metabolic disorder in which the insulin secretory response to glucose is impaired together with its effectiveness to stimulate glucose uptake by skeletal muscle and to restrain hepatic glucose production (insulin resistance), all of which combine to produce raised blood glucose levels (hyperglycemia).
In turn, this may lead to organ damage involving the kidneys (diabetic nephropathy), nervous system (diabetic neuropathy), eyes (diabetic retinopathy) and circulatory system.
Type 2 diabetes is often part of a metabolic syndrome that includes obesity, elevated blood pressure, and high levels of blood lipids. About 80 % of people with type 2 diabetes mellitus are overweight.
Wjat is Obesity?
is an excess of body fat, and is usually defined in terms of the body mass index (BMI), whereby a person with a BMI of greater than 30 kg/m2 is considered obese. At least 25 million Europeans are obese as well as tens of millions of people elsewhere around the world.
USa Obesity Epidemia
In the US, US$50 billion is spent every year on weight loss products and programs. In 2020, approximately US$800 million was spent on pharmaceutical treatments specifically approved for obesity, a figure that is forecast to grow approximately 20% per annum until 2025.
Global sales of obesity treatments are expected to be more than US$2.5 billion by 2025 (Nicholas Hall & Co). IMS Health also predicts rapid growth in this sector, with a sales forecast exceeding US$1.2 billion by 2025.